

Mr. Bock started his career as a Researcher in the early days at [Genentech, Inc.](#) in the field of infectious diseases, where he was on the team that received the [AAAS Newcomb Cleveland Prize](#) for demonstrating the world's first recombinant DNA vaccine. His most recent venture, [Aira](#), a visual services company for the blind in which he co-founded. He was a Venture Capital Associate with Fairfield Ventures (now Oxford Bioventures)

He has received several awards and honors. Mr. Bock was selected as by the US Commission for UNESCO as the nominee representing the United States of America in the international competition for the 2011 Kalinga Prize for the Popularization of Science. He was a recipient of the [Hoyt S. Vandenberg Prize](#) from the Air Force Association for the best STEM Education Program and also of the 2014 [Viktor Hamburger Outstanding Educator Prize](#) of the Society of Developmental Biology. He was selected by [Venture Capital Journal](#) as one of the "Ten Most Influential Venture Capitalists," by [Red Herring](#) as one of the "Top Ten Innovators," by [Forbes-Wolfe NanoReport](#) as the "Number One Powerbroker in Nanotechnology," by [Ernst & Young](#) as a Finalist for "Entrepreneur of the Year," and by [Small Times](#) as "Innovator of the Year" and "Top 3 Business Leaders of the Year." He received the [Einstein Award](#) by the Jerusalem Foundation for lifetime contributions in the field of life sciences. He was one of a dozen individuals invited to the signing of the 3.7B [21st Century Nanotechnology Act](#) by President George Bush in the Oval Office.

Mr. Bock was the Founder and Initial CEO of [Neurocrine Biosciences](#) (NASDAQ: NBIX – neuroimmunology), [Nanosys Inc.](#), [Pharmacopeia](#) (NASDAQ: PCOP - combinatorial chemistry (which spun off [Accelrys](#) (NASDAQ: ACCL – computer-aided-drug and material discovery)), [GenPharm International](#) (Private – transgenic animals, acquired by [Medarex](#) for 100M and also spun off [Pharming Group N.V.](#)), [Caliper Technologies](#) (NASDAQ: CALP – lab-on-a-chip and subsequently acquired by Perkin Elmer for \$650 Million), [Illumina Technologies](#) (NASDAQ: ILMN – human genotyping), [IDUN Pharmaceuticals](#) (Private – apoptosis, acquired by [Pfizer](#) (NYSE: PFE) for 250M)) [Metra Biosystems](#) (NASDAQ: MTRA – musculoskeletal disease diagnosis, merged with [Quidel](#) (NASDAQ: QDEL)), and [FASTTRACK Systems](#) (Private – accelerated clinical drug development). Mr. Bock was a co-founder of [Argonaut Technologies](#) (NASDAQ: AGNT – automated chemistry merged with [Biotope](#) (NASDAQ: BIOT)), [ARIAD Pharmaceuticals](#) (NASDAQ: ARIA – intra cellular signal transduction), [Athena Neurosciences](#) (NASDAQ: ATHN – molecular neurobiology, acquired by [Elan Pharmaceuticals](#) (NYSE: ELN) for 700M)), [Vertex Pharmaceuticals](#) (NASDAQ: VRTX – rational drug design), and [Onyx Pharmaceuticals](#) (NASDAQ: ONXX – molecular oncology). He also helped found and was previously on the Scientific Advisory Board of [Conforma Therapeutics](#) (Private – cellular chaperones – acquired by [Pfizer](#) for 250M).

Mr Bock was a seed stage investor in [Acceleron Pharma](#) (Private – metabolic and musculoskeletal diseases), [Aurora Biosciences](#) (NASDAQ: ABSC – high throughput drug discovery, acquired by [Vertex Pharmaceuticals](#) for 650M), [Cambrios](#) (Private – biology directed electronic assembly), [River Medical](#) (Private – drug delivery, purchased IVAC from [Eli Lilly](#) in an LBO and did a 700M merger with IMED to form [Alaris Medical](#) (NASDAQ: AMI – medical devices)), [Genocea Biosciences](#) (Private – vaccine

development) [Plexikon Pharmaceuticals](#) (Private – scaffold based drug design which was acquired by Daiichi Sankyo for \$800 M) [Poland Partners](#) (Private - a 62.5M venture capital fund investing in Central Europe), [Sequana Therapeutics](#) (NASDAQ: SQNA - genomics, merged with Arris Pharmaceuticals to form AXYS Pharmaceuticals (NASDAQ: AXPB) and subsequently acquired by [Celera Genomics](#) (NASDAQ: CRA)), [Sirtris Pharmaceuticals](#) (Private – gene regulation), [Software Transformation](#) (Private – object based software programming, acquired by [Novell](#) (NASDAQ: NOVL) for 25M), [Surface Logix](#) (Private – nano- imprint lithography), and [Talarian](#) (NASDAQ: TALR – real time, high content information processing over distributed networks merged with [TIBCO](#) (NASDAQ: TIBX)). He is also was previously on the Scientific Advisory Board of Protia L.L.C.

Larry was also an early stage venture investor in [Biosym Technologies](#) (Private – computer-aided-drug discovery – acquired by [Corning](#) (NYSE: GLW) for \$250M. [Gen-Probe](#) (NASDAQ: GNPR – DNA diagnostics, acquired by [Chugai Pharmaceuticals](#) for 180M), [Gensia Pharmaceuticals](#) (NASDAQ: GNSA – cardiovascular drugs, merged with Sicom to become [Gensia-Sicom](#) and subsequently acquired by [TEVA Pharmaceuticals](#) (NASDAQ: TEVA)), [IDEC Pharmaceuticals](#) (NASDAQ: IDEC – monoclonal antibody therapy, merged with Biogen to become [Biogen Idec](#) (NASDAQ: BIIB)), [Oclassen Pharmaceuticals](#) (Private - dermatology, acquired by [Watson Pharmaceuticals](#) (NYSE: WPI) for 180M), and [Viagene](#) (Private – gene therapy, acquired by [Chiron Corporation](#) for 100M).

Mr. Bock was involved in a number of government agencies. He was a Member of the Advisory Board and the Technology Advisory Board of the [NanoBusiness Alliance](#). He previously served as a Member of the Nanotechnology Technical Advisory Group (NTAG) reporting to the [President's Council of Advisors on Science and Technology](#) (PCAST), a Member of the [Blue Ribbon Task Force on Nanotechnology](#) formed by Congressman Mike Honda and California State Controller Steven Westly. He was on the Advisory Board of the [Faculty of Chemistry at the University of California, Berkeley](#).

Larry and his wife, Diane, established the Larry and Diane Bock Chair in Nanotechnology at the University of California, Berkeley held by [Dr. Paul Alivisatos](#). They also founded [Community Cousins](#), a non-profit foundation focused on breaking down racial barriers, which was selected by former Vice President Al Gore as one of ten outstanding grass root efforts nationally.

Larry received his B.A. in Biochemistry (summa cum laude) from [Bowdoin College](#) and his M.B.A. from the [Anderson School at UCLA](#).

Larry's accomplishments in life were a testament to his brilliance, passion, drive and love. He has been taken from us much too early. His future was bright with new endeavors and passions.

The Festival Family, supporters and sponsors have lost their trailblazer. The Festival legacy will continue in honor of the work Larry inspired.

In lieu of flowers or gifts, contributions may be made to [Science Spark](#) for producing the continuation of the USA Science and Engineering Festival, his crowning achievement. The Festival combines his love of science, entrepreneurship, jovial spirit, sense of adventure and his fondest hopes and dreams as a Dad.

Best Regards,

Marc Schulman
Executive Director
USA Science and Engineering Festival